Achieve Life Sciences (ACHV) CMO awarded 180,000 stock options at $4.36

Rhea-AI Filing Summary

Achieve Life Sciences Chief Medical Officer receives a new stock option grant. On January 28, 2026, Mark Lawrence Rubinstein was awarded stock options covering 180,000 shares of Achieve Life Sciences common stock at an exercise price of $4.36 per share.

The option will vest as to one quarter of the total award on the first anniversary of January 28, 2026, then in substantially equal monthly installments over the following 36 months, as long as he continues providing service to the company on each vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rubinstein Mark Lawrence

(Last) (First) (Middle)

22722 29TH DR. SE

SUITE 100

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ACHIEVE LIFE SCIENCES, INC. [ ACHV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.36	01/28/2026		A		180,000		(1)	01/28/2036	Common Stock	180,000	$0	180,000	D

Explanation of Responses:

1. The option will vest as to 1/4 of the total award on the first anniversary of January 28, 2026, and thereafter in substantially equal monthly installments over 36 months, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	Sandra Thomson as attorney-in-fact for Mark Rubinstein	01/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ACHV Chief Medical Officer Mark Rubinstein receive in this Form 4 filing?

Mark Lawrence Rubinstein received a stock option grant covering 180,000 shares of Achieve Life Sciences common stock at a $4.36 exercise price. This derivative award reflects part of his compensation as Chief Medical Officer and was reported as a directly owned derivative security.

When do Mark Rubinstein’s ACHV stock options start vesting and over what period?

The option begins vesting on the first anniversary of January 28, 2026, when 25% of the award vests. The remaining portion vests in substantially equal monthly installments over the next 36 months, contingent on his continued service to Achieve Life Sciences.

How many ACHV shares underlie Mark Rubinstein’s new stock option grant?

The stock option grant covers 180,000 shares of Achieve Life Sciences common stock. These shares are only obtainable if the options vest and are exercised at the $4.36 per share exercise price according to the disclosed vesting schedule.

What is the exercise price and expiration date of Mark Rubinstein’s ACHV options?

The options have a conversion or exercise price of $4.36 per share and expire on January 28, 2036. Rubinstein may exercise vested portions any time before expiration, subject to the company’s equity plan and continued service requirements.

How many ACHV derivative securities does Mark Rubinstein own after this transaction?

After this reported transaction, Mark Lawrence Rubinstein beneficially owns 180,000 derivative securities in the form of stock options. These options are held directly and relate to an equivalent number of underlying Achieve Life Sciences common shares.